Literature DB >> 12922932

Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists.

Winnie W C Shum1, Geng-Yun Le, Robert L Jones, Alison M Gurney, Yasuharu Sasaki.   

Abstract

1. The mechanism of contraction of guinea-pig isolated aorta induced by the prostanoid EP(3) receptor agonist sulprostone (0.1-300 nM) has been investigated. In 60% of the experiments, the sulprostone log concentration-response curve (maximum=15-40% of 100 nM U-46619 response; low-responders) was unaffected by the removal of extracellular Ca(2+), blockade of L-type Ca(2+) channels with nifedipine and depletion of internal Ca(2+) stores. In the remaining preparations (35-65% of 100 nM U-46619 response; high-responders), contractions to higher sulprostone concentrations showed a nifedipine-sensitive component, which was enhanced by charybdotoxin. 2. In Ca(2+)-free Krebs solution, established contractions to 300 nM sulprostone were abolished by the Rho-kinase inhibitors H-1152, Y-27632 and HA-1077 (IC(50) values=190, 770 and 2030 nM). The PKA/Rho-kinase inhibitor H-89 (10 nM-10 micro M) caused enhancement progressing to inhibition. The selective PKC inhibitor Ro 32-0432 (3 micro M) had no effect, while staurosporine, recently shown to be a potent Rho-kinase inhibitor, abolished sulprostone responses (IC(50) approximately 47 nM), but its action was slow. The MAP kinase inhibitors SB 202190, SB 203580 and PD 80958 produced little inhibition. 3. In normal Krebs solution, H-1152 and Y-27632 abolished established contractions to 300 nM sulprostone and 1 micro M phenylephrine, and partially inhibited 10 micro M phenylephrine and 50 mM K(+) responses. 4. The results are discussed in relation to the reported potencies of the protein kinase inhibitors in enzyme assays. Activation of the Rho-kinase pathway appears to be a primary mechanism of contraction induced by EP(3) receptor agonists in guinea-pig aorta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922932      PMCID: PMC1573987          DOI: 10.1038/sj.bjp.0705393

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

Review 1.  Prostaglandin receptors: advances in the study of EP3 receptor signaling.

Authors:  Noriyuki Hatae; Yukihiko Sugimoto; Atsushi Ichikawa
Journal:  J Biochem       Date:  2002-06       Impact factor: 3.387

Review 2.  Prostanoid receptors: structures, properties, and functions.

Authors:  S Narumiya; Y Sugimoto; F Ushikubi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

Review 3.  Receptor-operated Ca2(+)-permeable nonselective cation channels in vascular smooth muscle: a physiologic perspective.

Authors:  William A Large
Journal:  J Cardiovasc Electrophysiol       Date:  2002-05

Review 4.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

Authors:  R A Coleman; W L Smith; S Narumiya
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

Review 5.  Use of calcium pump inhibitors in the study of calcium regulation in smooth muscle.

Authors:  P J Darby; C Y Kwan; E E Daniel
Journal:  Biol Signals       Date:  1993 Sep-Oct

6.  SC-46275: a potent and highly selective agonist at the EP3 receptor.

Authors:  M A Savage; C Moummi; P J Karabatsos; T H Lanthorn
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1993-12       Impact factor: 4.006

7.  Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation.

Authors:  A M Birchall; J Bishop; D Bradshaw; A Cline; J Coffey; L H Elliott; V M Gibson; A Greenham; T J Hallam; W Harris
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

8.  Thromboxane A2/prostaglandin H2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase.

Authors:  T A Morinelli; L M Zhang; W H Newman; K E Meier
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

9.  Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor.

Authors:  Mami Ikenoya; Hiroyoshi Hidaka; Takamitsu Hosoya; Masaaki Suzuki; Naoki Yamamoto; Yasuharu Sasaki
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  Sensitivity to protein kinase C inhibitors of nicardipine-insensitive component of high K+ contracture in rat and guinea-pig aorta.

Authors:  A M Low; J C Loke; C Y Kwan; E E Daniel
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more
  15 in total

1.  Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

Authors:  R L Jones; D F Woodward; J W Wang; R L Clark
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2015-05       Impact factor: 3.386

3.  Protein kinase C delta contributes to increase in EP3 agonist-induced contraction in mesenteric arteries from type 2 diabetic Goto-Kakizaki rats.

Authors:  Keiko Ishida; Takayuki Matsumoto; Kumiko Taguchi; Katsuo Kamata; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2012-02-28       Impact factor: 3.657

4.  Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors.

Authors:  Y Ikeda-Matsuo; H Tanji; A Ota; Y Hirayama; S Uematsu; S Akira; Y Sasaki
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

6.  PGE2-EP3 signaling exacerbates intracerebral hemorrhage outcomes in 24-mo-old mice.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-15       Impact factor: 4.733

7.  Diverse effects of prostaglandin E₂ on vascular contractility.

Authors:  Taiki Kida; Kei Sawada; Koji Kobayashi; Masatoshi Hori; Hiroshi Ozaki; Takahisa Murata
Journal:  Heart Vessels       Date:  2013-06-09       Impact factor: 2.037

8.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

9.  PGE2 inhibits basolateral 50 pS potassium channels in the thick ascending limb of the rat kidney.

Authors:  Ruimin Gu; Yan Jin; Yuanyuan Zhai; Lei Yang; Chengbiao Zhang; Wennan Li; Lijun Wang; Shumin Kong; Yunhong Zhang; Baofeng Yang; Wen-Hui Wang
Journal:  Kidney Int       Date:  2008-05-21       Impact factor: 10.612

10.  The deleterious role of the prostaglandin E2 EP3 receptor in angiotensin II hypertension.

Authors:  Timothy D Bryson; Teja S Pandrangi; Safa Z Khan; Jiang Xu; Tengis S Pavlov; Pablo A Ortiz; Edward Peterson; Pamela Harding
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.